Guardant Health Co-CEO sells 50,000 shares

Guardant Health, Inc. Co-Chief Executive Officer and director AmirAli Talasaz reported an open-market sale of 50,000 shares of Common Stock on May 12, 2026.

Rhea-AI Filing Summary

Guardant Health, Inc. Co-Chief Executive Officer and director AmirAli Talasaz reported an open-market sale of 50,000 shares of Common Stock on May 12, 2026. The shares were sold at a weighted average price of $100.32 per share in multiple trades.

After this transaction, 2,096,504 shares of Guardant Health Common Stock are reported as indirectly owned, held by the Talasaz and Eskandari 2017 Family Trust.

Insider Trade Summary 10b5-1

Net Seller: 50,000 shares

Net Sell 1 txn

Insider Talasaz AmirAli

Role Co-Chief Executive Officer

Sold 50,000 shs ($5.02M)

Type	Security	Shares	Price	Value
Sale	Common Stock	50,000	$100.32	$5.02M

Holdings After Transaction: Common Stock — 2,096,504 shares (Indirect, Shares held by Talasaz and Eskandari 2017 Family Trust)

Footnotes (1)

1. F1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.30 to $100.34. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 50,000 shares Average sale price: $100.32 per share Price range: $100.30–$100.34 per share +1 more

4 metrics

Shares sold 50,000 shares Open-market sale on May 12, 2026

Average sale price $100.32 per share Weighted average sales price for 50,000 shares

Price range $100.30–$100.34 per share Range of individual trade prices in the sale

Shares owned after transaction 2,096,504 shares Indirect holdings via Talasaz and Eskandari 2017 Family Trust after sale

Key Terms

open-market sale, weighted average sales price, indirect ownership, Family Trust

4 terms

open-market sale financial

"The transaction is described as an open-market sale of Common Stock."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sales price financial

"Represents the weighted average sales price per share."

indirect ownership financial

"Ownership type is reported as indirect, held by a family trust."

Family Trust financial

"Shares held by Talasaz and Eskandari 2017 Family Trust."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Guardant Health (GH) disclose for AmirAli Talasaz?

Guardant Health disclosed that Co-Chief Executive Officer and director AmirAli Talasaz reported an open-market sale of 50,000 shares of Common Stock on May 12, 2026. The transaction was executed through the Talasaz and Eskandari 2017 Family Trust.

At what price were the Guardant Health (GH) shares sold in the latest Form 4?

The 50,000 Guardant Health shares were sold at a weighted average price of $100.32 per share. Footnotes state the sales occurred in multiple transactions, at prices ranging from $100.30 to $100.34 across the executed trades.

How many Guardant Health (GH) shares does AmirAli Talasaz report owning after the sale?

Following the reported sale, 2,096,504 shares of Guardant Health Common Stock are shown as indirectly owned. These holdings are reported as being held by the Talasaz and Eskandari 2017 Family Trust rather than directly in AmirAli Talasaz’s name.

Is the recent Guardant Health (GH) insider sale classified as an open-market transaction?

Yes. The Form 4 classifies the transaction as an open-market sale of Common Stock, using transaction code “S.” The filing describes it as a sale in the open market or a private transaction, with the shares sold across multiple price points.

Who legally holds the Guardant Health (GH) shares involved in the Form 4 transaction?

The shares are reported as indirectly owned and held by the Talasaz and Eskandari 2017 Family Trust. The Form 4 lists ownership type as indirect, with the nature of ownership explicitly referencing this family trust as the holding entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 05:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Talasaz AmirAli

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/12/2026		S		50,000	D	$100.32(1)	2,096,504	I	Shares held by Talasaz and Eskandari 2017 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.30 to $100.34. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for AmirAli Talasaz	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)